Literature DB >> 23736960

[Rational imaging of metastasized tumor diseases].

H J Stemmler1, M Schlemmer, S Reilich.   

Abstract

Most anticancer medications are effective only in subgroups of patients. Despite considerable improvements in histopathological and molecular pathological diagnostics, tumor response in the individual patient still remains unpredictable. Measuring tumor shrinkage by cross-sectional imaging procedures in patients with metastatic cancer represents the current standard for documenting the effectiveness of anticancer therapy. In addition to the large number of different imaging procedures computed tomography (CT) is certainly the best established and most widely available technique for assessing tumor response. This manuscript reviews the necessity and rationality of imaging procedures for monitoring tumor response in patients with metastatic cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23736960     DOI: 10.1007/s00108-012-3241-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  39 in total

1.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.

Authors:  Martin Hutchings; Annika Loft; Mads Hansen; Lars Møller Pedersen; Thora Buhl; Jesper Jurlander; Simon Buus; Susanne Keiding; Francesco D'Amore; Anne-Marie Boesen; Anne Kiil Berthelsen; Lena Specht
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

2.  Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.

Authors:  Stefan Boeck; Michael Haas; Rüdiger P Laubender; Frank Kullmann; Christina Klose; Christiane J Bruns; Ralf Wilkowski; Petra Stieber; Stefan Holdenrieder; Hannes Buchner; Ulrich Mansmann; Volker Heinemann
Journal:  Clin Cancer Res       Date:  2010-01-26       Impact factor: 12.531

3.  [Prognostic value of (18)F-FDG PET/CT after first-line treatment in patients with diffuse large B cell lymphoma].

Authors:  Zhi-tao Ying; Xue-juan Wang; Yu-qin Song; Wen Zheng; Xiao-pei Wang; Yan Xie; Ning-jing Lin; Mei-feng Tu; Ling-yan Ping; Wei-ping Liu; Li-juan Deng; Chen Zhang; Zhi Yang; Jun Zhu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2012-10

4.  Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.

Authors:  Lia M Halasz; Heather A Jacene; Paul J Catalano; Annick D Van den Abbeele; Ann Lacasce; Peter M Mauch; Andrea K Ng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

Review 5.  Role of FDG-PET staging in selecting the optimum patient for hepatic resection of metastatic colorectal cancer.

Authors:  Steven M Strasberg; Farrokh Dehdashti
Journal:  J Surg Oncol       Date:  2010-12-15       Impact factor: 3.454

6.  Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

Authors:  E Van Cutsem; H van de Velde; P Karasek; H Oettle; W L Vervenne; A Szawlowski; P Schoffski; S Post; C Verslype; H Neumann; H Safran; Y Humblet; J Perez Ruixo; Y Ma; D Von Hoff
Journal:  J Clin Oncol       Date:  2004-04-15       Impact factor: 44.544

7.  Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials.

Authors:  Primo N Lara; Mary W Redman; Karen Kelly; Martin J Edelman; Stephen K Williamson; John J Crowley; David R Gandara
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

8.  Computed tomography and positron emission tomography/computed tomography surveillance after combined modality treatment of supradiaphragmatic Hodgkin lymphoma: a clinical and economic perspective.

Authors:  Vatsal Patel; Michael Buckstein; Rodolfo Perini; Christine Hill-Kayser; Jakub Svoboda; John P Plastaras
Journal:  Leuk Lymphoma       Date:  2013-02-12

9.  Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival.

Authors:  Katherine R Birchard; Jenny K Hoang; James E Herndon; Edward F Patz
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

10.  Hookah smoking and cancer: carcinoembryonic antigen (CEA) levels in exclusive/ever hookah smokers.

Authors:  Khan Mohammad Sajid; Kamal Chaouachi; Rubaida Mahmood
Journal:  Harm Reduct J       Date:  2008-05-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.